- Molecular NameCerivastatin
- SynonymCerivastatin sodium; Cerivastatin, sodium salt
- Weight459.558
- Drugbank_IDN/A
- ACS_NO145599-86-6
- Show 2D model
- LogP (experiment)4.669
- LogP (predicted, AB/LogP v2.0)3.98
- pkaN/A
- LogD (pH=7, predicted)1.31
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.93
- LogSw (predicted, AB/LogsW2.0)0.05
- Sw (mg/ml) (predicted, ACD/Labs)0.03
- No.of HBond Donors3
- No.of HBond Acceptors6
- No.of Rotatable Bonds11
- TPSA99.88
- StatusN/A
- AdministrationN/A
- PharmacologyA synthetic member of the class of statins used to lower cholesterol and prevent cardiovascular disease.
- Absorption_valueN/A
- Absorption (description)Cerivastatin is readily and almost completely absorbed after oral administration.
- Caco_2N/A
- Bioavailability60.0
- Protein binding99.0
- Volume of distribution (VD)0.3 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt undergoes metabolism in the liver and is catalysed by at least two cytochrome P450 isoenzymes, CYP2C8 and CYP3A4. Three active metabolites are formed. The demethylated metabolite (about 50% as potent as the parent drug) and the hydroxylated metabolite (about 80% as potent) are the major metabolites formed; the product of both demethylation and hydroxylation also has activity, but it is only a minor metabolite.
- Half life2~3 h
- ExcretionThe metabolites are excreted in urine (about 30%) and in faeces (about 70%). There is no unchanged drug found in urine. There is no significant clearance by haemodialysis.
- Urinary ExcretionN/A
- Clerance0.2 L/h/kg
- ToxicityRhabdomyolysis, liver concerns
- LD50 (rat)N/A
- LD50 (mouse)N/A